Skip to content

Saturday, November 21, 2026News that matters to Black communities

Black adults take GLP-1 drugs at nearly twice the white rate. The FDA just added a vision-loss warning

In FDA's analysis of trials, 6.4 in 100,000 users a year had the eye condition, against 3.8 for comparison groups

Newsroom · 2 min read · 0 comments
XFacebookBluesky

The Food and Drug Administration has ordered every maker of a GLP-1 drug to warn about a rare form of sudden vision loss. Black adults are among the people most likely to be taking them: in a 2024 KFF poll, 18% of Black adults said they had ever used one, against 10% of white adults and 13% of Hispanic adults.

The FDA announced the labeling change on Nov. 9. It covers Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound and the rest of the class, and it adds the condition, non-arteritic anterior ischemic optic neuropathy (NAION), to the Warnings and Precautions section. NAION happens when blood flow drops to the optic nerve. It can cause permanent vision loss in one eye.

The risk is small. In the FDA’s analysis of 126 randomized trials covering 134,253 patients, NAION occurred in 6.4 of every 100,000 people a year on a GLP-1 drug, against 3.8 per 100,000 among people on a placebo or other diabetes drugs. Real-world data the agency reviewed showed higher rates, 30 to 32 events per 100,000 person-years. The FDA says the underlying cause “isn’t understood.”

What patients are told to do is specific. Anyone who notices sudden, painless blurring, blind spots or other changes in one eye, often on waking, should contact a health professional immediately and get an eye exam. A patient who develops NAION should talk with their doctor about whether to stay on the drug. Nobody is being told to stop taking it on their own.

Why this reaches Black patients

KFF, citing CDC data, notes that Black and Hispanic adults have higher obesity rates than white adults, which is the reason it gives for the gap in use. The poll was fielded April 23 to May 1, 2024, among 1,479 adults. The margin of error is 3 points for the full sample and 9 points among the 189 people who reported using a GLP-1, so the 18% and 10% are estimates, not exact counts.

The announcement, as reported, gives no breakdown of NAION cases by race. That is the missing piece. If more Black patients are taking these drugs, the public deserves to know whether they are affected differently, and the label change does not answer it. Race data should be part of the FDA’s follow-up on this warning, and drugmakers should be asked to report it.

The warning is also a reason to protect eye care, not to scare anyone off a medicine that treats diabetes. That means insurers covering the exam, and doctors telling patients the symptoms before a prescription is filled, not after. Updated labels are due from the manufacturers.

Membership

If this mattered to you, help pay for the next one.

No billionaire or corporation pays for The Black Observer. Its readers do. Members get two exclusive opinion columns a week and the monthly edition, and keep the reporting free for everyone else.

The Record
$5 / month
  • Two exclusive columns a week, never published on the site
  • Monday, The Argument: Tanish's position on a question that matters
  • Thursday, The Numbers: the data behind it, with charts
  • Members-only threads: reply, and she answers
Join The Record
Most popular
Digital Edition
$10 / month

Everything in The Record, plus:

  • The Black Observer monthly magazine, digital, on the 1st of every month
  • Every past edition, to read or download
Join Digital Edition
Print Edition
$30 / month

Everything in Digital Edition, plus:

  • The printed magazine, mailed to your address in the US or Canada
  • Your name on the supporters page of every edition
Join Print Edition

Billed monthly through Patreon, in US dollars. Change tier or cancel anytime.

The conversation 0

No comments yet. Start the conversation.

Have your say

No sign-up needed. We publish straight away; comments with links are looked at first. Criticise ideas, not people. By commenting you accept the community guidelines and the privacy policy.

We use cookies to understand how readers find and use the site. You can say no. Privacy